Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06909695 · ClinicalTrials.gov registry record
Influences of Long-acting Reversible Contraceptives on Iron Status and Physiological Responses to Extreme Environments in Women
A clinical trial of Contraception and Iron Deficiencies, sponsored by United States Army Research Institute of Environmental Medicine.
- Recruiting
- Registry status
- 33
- Enrollment target
- 1
- Study location
NCT06909695: Recruiting study of Contraception and Iron Deficiencies, sponsored by United States Army Research Institute of Environmental Medicine.
NCT06909695 is a study of Contraception and Iron Deficiencies that is actively recruiting participants, run by United States Army Research Institute of Environmental Medicine. The registered enrollment target is 33 participants, below the 454-participant average among 72 other Contraception trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06909695, a study of Contraception and Iron Deficiencies, is actively recruiting participants, sponsored by United States Army Research Institute of Environmental Medicine.
- RECRUITING
- Registry status
- 33 participants
- Enrollment target
- 1
- Study location
Study Summary
Over recent years, military service women have shown increasing interest in utilizing long-acting reversible contraceptives (LARCs; i.e., implants or intrauterine devices, IUDs). While clinically, LARC have been proven safe and effective at preventing pregnancy \& decreasing menstrual symptoms, it is unclear what impact this type of contraceptive may have on physiological responses to extreme environments (heat, cold and high altitude). Additionally, iron deficiency and iron deficiency anemia are prevalent in U.S. military women which likely affect health and performance. There is evidence to suggest that the prevalence of iron deficiency and iron deficiency anemia is lower in women utilizing LARCs, which preserve iron stores, likely due to reduced menstrual blood loss that compounds with each cycle over the course of months. Due to the increasing interest in the utilization of LARCs it is important to understand what, if any, impact these methods of contraception may have on a female Soldier's physiological responses. The overall goal of the present study is to characterize iron status and physiological responses (including but not limited to sweating, skin blood flow, ventilation, and heart rate) to extreme environmental stressors of heat, cold and high altitude (i.e. hypobaric hypoxia) in women utilizing LARCs. Up to thirty-three individuals (n=18 LARCs, n=15 monophasic oral contraceptives) will complete testing visits separated by at least 48 hours for environmental testing visits. During heat stress testing, measures of core body temperature, skin temperature, and sweat rate will be measured during a standardized protocol in hot, humid conditions. During cold stress, measures of body core temperature, metabolic heat production, skin blood flow and temperature (at both distal extremity and proximal body sites) will be assessed in order to better quantify the impact of exogenous sex hormones via LARCs and OCs in volunteers exposed to the cold. Measurements will
Primary Outcome
Iron stores as measured by ferritin levels
Conditions Studied
Interventions
- OTHER Blood volume and environmental testing
Study Locations (1)
Massachusetts
- US Army Research Institute of Environmental Medicine - Natick
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2024-11-01 |
| Est. Completion | 2027-09 |
What NCT06909695 shows while recruiting
NCT06909695 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 454-participant average among 72 other Contraception trials with a reported enrollment target (93% lower).
The record links to 2 conditions, with Contraception appearing as the primary indexed condition, and to 1 intervention - of which Blood volume and environmental testing is the first listed.
NCT06909695 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06909695 about?
NCT06909695 is a clinical study titled "Influences of Long-acting Reversible Contraceptives on Iron Status and Physiological Responses to Extreme Environments in Women". Over recent years, military service women have shown increasing interest in utilizing long-acting reversible contraceptives (LARCs; i.e., implants or intrauterine devices, IUDs). While clinically, LARC have been proven safe and effective at preventing pregnancy \& decreasing menstrual symptoms, it i...
What is the current status of trial NCT06909695?
This trial is currently recruiting. The enrollment target is 33 participants. The study started on 2024-11-01. Estimated completion is 2027-09.
What conditions does trial NCT06909695 study?
This clinical trial studies the following conditions: Contraception, Iron Deficiencies.
What interventions are being tested in trial NCT06909695?
The interventions under investigation include: Blood volume and environmental testing (OTHER).
Who is sponsoring clinical trial NCT06909695?
This trial is sponsored by United States Army Research Institute of Environmental Medicine, which has 59 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06909695 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Contraception
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06909695's enrollment target sits among peer trials
33 58th of 72 higher than 15 of 72 other Contraception trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Contraception trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Oral Contraceptive Pill (OCP) Pharmacogenomics
RECRUITING · Phase 4
-
Intravenous Ketorolac Administration to Attenuate Post-procedural Pain Associated With Intrauterine Device Placement
RECRUITING · Phase 4
-
Patient-clinical Linkages to Improve Trust and Engagement in Postpartum Healthcare
RECRUITING · NA
-
Empathy Through Pain Control: Lidocaine Paracervical Block for IUD Placements
RECRUITING · NA
-
Hormonal Contraception Access Through Pharmacist Prescribing Implementation
RECRUITING · NA
-
Prospective Multi-Center Trial for FemBloc Permanent Birth Control
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI